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The Non-Genomic Effects of the PPARβγ agonist GW0742 on STZ treated 
rat aorta 
Noelia Perez-Diaza, Igor Pushkarskya, Nadia Oweisa, Lisa A. Lionea, Louise S. Mackenzie*a 
a School of Life and Medical Sciences, Hertfordshire University, Hatfield, UK  
Background: The ubiquitous nuclear receptor PPARβ/δ is increasingly being studied in regards to 
numerous diseases including diabetes following on the finding that PPARβ/δ agonist GW0742 controls 
Type 1 Diabetes in rats. Studies have shown that GW0742 has off target, non- PPARβ/δ effects in the 
cell although there are some key questions that remain to be addressed in respect to the significance of 
this control on vascular tone.  
Methods: Using isometric organ baths, rat aorta rings were exposed to ROCK inhibitors and the changes in 
contraction and dilation measured.  
Results: Our data shows that the PPARβ/δ agonist GW0742 (10-7M) inhibits contractile responses to U46619 and 
phenylephrine, and that these responses are similar in normal and diabetic rat aorta. ROCK inhibitors Fasudil 
and Y27632 significantly reduced GW0742 mediated dilation of naïve rat aorta, but Fasudil had no effect on 
GW0742 dilation in STZ diabetic rat aorta. In contrast, STZ diabetic rat aorta pre-contracted with high [K+] 
Krebs lacked a dilatory response to GW0742, which taken together indicates that the mechanism of action of 
GW0742 mediated dilation changes in the diabetic state compared to non-diabetic state.  
Conclusion: This is the first direct evidence demonstrating the non- PPARβ/δ effect of GW0742 on contraction is 
irrespective to the diabetic state, and that GW0742 has the potential to induce vasodilation via multiple off-target 
mechanisms. 
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1. INTRODUCTION 
 Peroxisome proliferator activated receptors (PPARs) are 
ligand-activated transcription factors and members of the 
nuclear hormone receptor superfamily. PPARβ/δ is present 
in all animal cells, from close versions in C. elegans and 
drosophila to all mammals tested, yet the biology of how this 
ubiquitous protein controls gene expression is poorly 
understood. Signaling via PPARβ/δ has a number of effects 
on cell function, including lipid metabolism [1], glucose 
metabolism [2], insulin sensitivity [2], and inflammation [3]. 
There are complex mechanisms by which PPARβ/δ controls 
gene transcription through induction and transrepression of 
other nuclear receptors which are yet to be fully defined [4].   
1.1. GW0742 is a potential therapeutic agent 
The PPARβ/δ agonist GW501516 completed proof-of-
concept clinical trials successfully for hypocholesteremia [1], 
with further potential as treatments for Type I diabetes [5, 6]. 
Direct activation of PPARβ/δ with agonist GW0742 (a close 
mimetic of GW501516) in rats treated with Streptozotocin 
(STZ; a model of Type I diabetes) improves insulin signaling 
[5] and glucose homeostasis [6]. Therefore GW0742 has the 
potential to be a novel therapeutic agent.  
1.2. Non-Genomic Effects of PPARβ/δ 
 Surprisingly for a nuclear receptor, PPARβ/δ has non-
genomic roles within the cell, showing direct binding and 
activity with proteins to alter the function of cells. The first 
example of this phenomenon was demonstrated in platelets, 
where the direct binding of activated PPARβ/δ receptor to 
PKCα inhibited aggregation [7]. Previous studies have 
shown that GW0742 inhibits contraction [8], but little is 
known about the concentration range at which this occurs, 
and whether the same phenomenon is seen in diabetes. The 
PPARβ/δ agonist GW0742 induces full vasodilation of aorta, 
pulmonary artery and mesenteric artery, and it has been 
proposed that this occurs due to the inhibition of GTP-RhoA 
formation [8]. Active GTP-RhoA activates Rho associated 
protein kinase (ROCK), the downstream effector protein; 
inhibition of either RhoA or ROCK will induce a lack of 
contraction. Direct pharmacological evidence of the effects 
of GW0742 on inhibiting ROCK mediated contraction has so 
far not been demonstrated possibly due to the complication 
of ROCK inhibition inducing a lack of contractile tone. 
ROCK is involved in contractile responses to phenylephrine 
and to a much lesser extent U46619 [9]. Here we used a 
protocol that allowed measurement of GW0742 on ROCK 
independent U46619 contraction. Our results demonstrate 
that GW0742 inhibits contraction of aorta from naïve and 
STZ Type 1 diabetic rat, and that GW0742 induces 
vasodilation mediated in part by the RhoA/ROCK pathway 
in naïve rat aortas and potassium channels in STZ diabetic 
rat aortas. 
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 2. MATERIALS AND METHODS  
 Male Wistar rats (350-450g) sourced from Charles River 
were housed in pairs and given a single injection of 65mg/kg 
Streptozotocin (STZ; dissolved in 20mM citrate buffer, pH 
4.5) intraperitoneally (i.p. 10ml/kg). For 48 hours following 
STZ or control injection (20mM citrate buffer) an additional 
choice of 2% sucrose solution was provided to avoid the 
initial hypoglycemia that is seen following STZ.  Rats were 
monitored for a minimum of 2 weeks post-injection, and 
diabetes was confirmed by testing a drop of tail vein blood 
(Accu-check blood glucose monitor); rats showing an 
elevated blood glucose of >16mmol/L were considered 
diabetic and used in this study.  
The rats were killed by CO2 asphyxiation and their thoracic 
aortas were rapidly removed and dissected in Krebs’s buffer 
(pH 7.4, 118mM NaCl, 4.7mM KCl, 1.2mM MgSO4, 1.2mM 
KH2PO4, 2.5mM CaCl2, 25.0mM NaHCO3 and 11.0mM 
glucose). Aortas were cut into 2mm wide rings after 
removing the surrounding connective tissue and fat. Each 
ring was suspended with silk thread in a 20ml organ bath 
filled with Krebs’s buffer and maintained at 37°C. The upper 
end of the silk was connected to a force transducer and the 
lower one connected to an L-shaped mounting hook, and the 
aorta rings maintained an isometric force of 2g for a one 
hour equilibration time and then throughout the experiments. 
The bath solution was continuously bubbled with 95% O2 
and 5% CO2.  
Aorta rings from naïve and STZ diabetic rats were incubated 
with 10-9, 10-8 or 10-7M GW0742 or vehicle control (DMSO; 
final bath concentration 0.01%) for 30 minutes, followed by 
increasing concentrations of phenylephrine (10-8 to 10-5M) or 
U46619 (10-9 to 3x10-7M). Some tissues were incubated with 
ROCK inhibitors Fasudil (10-6M) or Y27632 (10-6M) for 30 
minutes followed by a response to increasing concentrations 
of U46619 (10-9 to 3x10-7M).  
In order to measure the ROCK inhibitory effects of W0742, 
arteries were exposed to 10-6M Fasudil or 10-6M Y27632 for 
30 minutes, pre-contracted with 10-7M U46619 and exposed 
to increasing concentrations of GW0742 (10-6M to 3x10-5M). 
In order to determine the extent to which potassium channels 
are involved in GW0742 mediated dilation, some aorta rings 
were pre-contracted with high potassium Krebs’s buffer (pH 
7.4, 124mM KCl, 1.2mM MgSO4, 1.2mM KH2PO4, 2.5mM 
CaCl2, 25.0mM NaHCO3 and 11.0mM glucose) followed by 
increasing concentrations of GW0742 (10-6M to 3x10-5M). 
3. EXPERIMENTAL 
 Vasodilation is expressed as percentage of the U46619 
mediated pre-contraction obtained prior to the addition of 
GW0742. Data are presented as mean ± SEM; n refers to the 
number of rats used. Statistical analysis was performed by 
two way analysis of variance using GraphPad Prism 5.0, and 
differences were considered to be significant when P was 
less than 0.05.  
 
 
 
4. RESULTS  
 Effect of increasing concentrations of GW0742 on rat 
aorta contraction 
Phenylephrine induced contraction of aorta from diabetic rats 
is significantly increased compared to aorta from naïve rat 
aortas (Figure 1A), in comparison to U46619 mediated 
contraction which shows no significant difference (Figure 
1B). U46619 may only be tested up until a concentration of 
3x10-7M since any further addition induces an irreversible 
contraction.  
Figure 1. Change in tension induced by A. Phenylephrine 
(PE), B. U46619 in naïve and STZ diabetic rat aorta; data is 
represented as mean ± SEM. Significant difference 
compared to vehicle controls was analysed by two-way 
ANOVA and denoted by ***= p<0.001, ‘ns’= non-
significance; n=4-6 
Aorta segments from naïve and STZ diabetic rats responded 
to increasing concentrations of GW0742 in a similar manner. 
Incubation in the presence of 10-9M and 10-8M GW0742 had 
no effect on U46619 or phenylephrine (Table 1) mediated 
contraction in aorta from naïve or STZ diabetic rats. 
Whereas 10-7M GW0742 significantly decreased contraction 
to U46619 and phenylephrine (Table 1) in both naïve and 
STZ diabetic rat aorta. 
Table 1.  Change in tension induced by U46619 in naïve 
control and STZ diabetic rat aorta following incubation with 
10-9M, 10-8M or 10-7M GW0742. Emax is represented as mean 
± SEM. Significant difference compared to vehicle controls 
was analysed by two-way ANOVA and denoted by * = 
p<0.05, ***= p<0.001; n=4-6 for all groups  
 
Effects of ROCK inhibitors on aorta contraction 
ROCK inhibitors Y27632 and Fasudil led to a loss of 
phenylephrine mediated contraction in naïve rat aorta 
segments from Emax 0.427 ± 0.05g Vehicle control to 0.053 ± 
0.02g Y27632 treated and 0.174 ± 0.062g Fasudil treated rat 
aortas (Figure 2A). In contrast, ROCK inhibitors reduced 
U46619 mediated contraction in naïve rat aorta with Emax 
0.551 ± 0.07g to Emax 0.313 ± 0.04 when incubated with 
Y27632 and Emax 0.45 ± 0.09g with Fasudil (Figure 2B). 
STZ diabetic rat aorta contraction in response to U46619 
(Emax from 0.811 ± 0.07g in Vehicle control) was 
significantly reduced by Fasudil to Emax 0.449 ± 0.03g, and 
completely inhibited by Y27632 aortas to Fasudil treated 
aortas (Emax 0.121 ± 0.03g; Figure 2C). 
Figure 2. Contraction in response to A. Phenylephrine (PE, 
B. U46619 in naïve rat aorta, C. U46619 in STZ diabetic rat 
aorta following incubation with 10-5M Y27632 and 10-5M 
Fasudil; data is represented as mean ± SEM. Significant 
difference compared to vehicle controls was analysed by 
two-way ANOVA and denoted by **= p<0.01, ***= 
p<0.001, ‘ns’ non-significance; fff=p<0.001 by Bonferroni’s 
post hoc test; n=4. 
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Effects of ROCK inhibitors on GW0742 mediated 
vasodilatation 
Aorta pre-contracted in the presence of EC80 U46619 and 
exposed to increasing concentrations of GW0742 results in a 
full relaxation response (Emax relaxation -79.4 ± 4.5%; EC50 
1.5x10-5M; Figure 3A), which is significantly reduced in 
STZ diabetic rat aorta (Emax relaxation -54.5 ± 8.6% EC50 1.7 
x10-5M; Figure 3A). When pre-contracted by high [K+] 
Krebs, the Emax relaxation in response to GW0742 in naïve 
control rat aorta was -39.3 ± 1.9%, significantly reduced in 
STZ diabetic rat aorta to Emax relaxation -20.7 ± 2.5% 
(Figure 3B). Fasudil significantly reduced the GW0742 
mediated dilation in naïve rat aorta from Emax relaxation 79.4 
± 4.5% in vehicle controls to -54.2 ±3.7% Fasudil treated 
naïve rat aortas (Figure 3C), but not in STZ diabetic rat aorta 
(Emax relaxation -54.5 ± 8.6% vehicle control and -64.3 ± 
8.4% Fasudil incubated STZ diabetic rat aorta; Figure 3D). 
Figure 3. Dilation of Naïve and STZ diabetic rat aorta to 
GW0742 following pre-contraction to A. U46619 and B. 
high potassium solution (124mM K+). The effects of 10-5M 
Fasudil on GW0742 mediated vasodilation in C. naïve rat 
aorta and D. STZ diabetic rat aorta. Rat aorta were 
incubated with 10-5M Fasudil for 30 minutes, pre-contracted 
with EC80 U46619 and exposed to increasing concentrations 
of GW0742. Data is represented as mean ± SEM. Significant 
difference compared to vehicle controls was analysed by 
two-way ANOVA and denoted by *= p<0.05, ***= p<0.001, 
‘ns’ non-significance; f =p<0.05, fff=p<0.001 by 
Bonferroni’s post hoc test; n=4. 
5. CONCLUSION 
While it has previously been noted that 10-5M GW0742 
significantly inhibits U46619 mediated vasocontraction [8], 
the concentration at which this inhibition occurs was not 
known, nor whether this would be altered in a diabetic state 
[8]. Here we show that in both naïve and STZ diabetic rats 
10-7M GW0742 significantly reduces U46619 and 
phenylephrine mediated contraction, a concentration 
selective for PPARβ/δ [10, 11]. While GW0742 direct 
actions on PPARβ/δ function can reduce the effects of 
diabetes, the off target effects of GW0742 were deemed to 
also be beneficial in controlling vascular tone. Our data 
indicates that these off target effects of GW0742 on vascular 
tone is similar in naïve and STZ diabetic aorta, although the 
mechanism of actions differs. 
In previous studies, GW0742 was shown to inhibit the 
formation of GTP bound RhoA using aorta tissue extracts in 
an ELISA assay [8]. While this study is of interest in 
outlining an important relationship between GW0742 and 
RhoA-GTP formation, the consequence of this interaction on 
contractility remained to be defined in native aorta tissue 
bath experiments. 
The RhoA/ROCK pathway mediates smooth muscle 
contraction; inhibition of this pathway decreases 
cardiomyopathy in Type 1 diabetic rat models [12]. 
Inhibition of ROCK/RhoA prevents contraction [9], making 
the investigation of a ROCK inhibitor’s effects on 
contraction difficult to determine directly. Our approach was 
to use a contractile agent that induced a non-RhoA mediated 
contractile response, and measure the effects of GW0742 on 
tone. In order to achieve this, we incubated aorta with ROCK 
inhibitors Fasudil and Y27632, and contracted with U46619 
or phenylephrine. The phenylephrine mediated contraction 
was largely abolished following ROCK inhibition in naïve 
aorta as shown previously [9, 13] thus precluding the use of 
this contractile agent in the GW0742 dilatory protocol. In 
contrast, U46619 contraction was significantly reduced 
following ROCK inhibition but still of sufficient tone for 
further experimentation. This result confirms previous data 
showing that U46619 contracts using partially different 
contractile machinery to phenylephrine [13]. 
Studies have been conducted to determine the mechanisms 
by which the activated PPARβ/δ induces vasodilation in 
arteries, possibly mediated by direct interaction with RhoA 
[8, 14], activation of PI3-Akt-eNOS pathways [15] or 
activation of K+ channels [16]. In order to address the 
question as to whether PPARβ/δ directly interferes with the 
RhoA/ROCK pathway and K+ channels, we took advantage 
of the dilatory properties of the agonist GW0742. The 
dilatory effect of GW0742 was significantly reduced in STZ 
diabetic rat aorta compared to naïve controls, which indicates 
that the mechanism by which PPARβ/δ induces a loss of 
tone is affected by the diabetic state.  
In order to investigate the contribution of potassium channels 
to GW0742 mediated dilation, we induced depolarization of 
the smooth muscle cells with high [K+] Krebs which 
inhibited GW0742 induced depolarization. While GW0742 
mediated dilation was inhibited in naïve rat aorta pre-
contracted with high [K+] Krebs, it was abolished in STZ 
diabetic rat aorta, which indicates that the GW0742 mediated 
dilation of aorta involves K+ channels more in the diabetic 
state than in the normal physiological state. 
In our protocol, aortas were incubated with Y29632 or 
Fasudil for 30 minutes, a time frame that is too short to allow 
for new genes to be inducted. As expected from previous 
results, both Y29632 and Fasudil reduced U46619 EC80 
contraction, although to a level that can still be used to 
maintain a contractile state to witness relaxation induced by 
GW0742. While the ROCK inhibitors reduced the U46619 
mediated contraction, there was sufficient tone to measure 
GW0742 mediated dilation, although Y27632 abolished the 
U46619 mediated contraction in STZ diabetic rat aortas, 
making dilatory responses impossible to determine. The 
vasodilatory response elicited by 10-5M GW0742 in naïve rat 
aorta was significantly inhibited by Fasudil incubation, 
providing direct pharmacological evidence that GW0742 
stimulation of PPARβ/δ inhibits the RhoA/ROCK pathway 
in contracted arteries. Interestingly, Fasudil had no effect on 
GW0742 mediated dilation in STZ diabetic rat aorta. Taken 
together with the data of aorta pre-contracted with high [K+] 
Krebs, this indicates that there is a shift in PPARβ/δ 
mediated dilation from ROCK pathway mechanism in naïve 
rats to more of a K+ channel involvement in STZ diabetic rat 
aortas. 
PPARβ/δ agonist GW0742 decreases contractile responses to 
U46619 in both naïve and STZ diabetic rat aorta. Here we 
show direct pharmacological evidence that GW0742 induces 
vasodilation mediated in part by the RhoA/ROCK pathway 
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in naïve rat aortas and potassium channels in STZ diabetic 
rat aortas.. 
6. STANDARD PROTOCOL ON ANIMAL 
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     The care and use of all rats in this study was carried out in 
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